Effects of Edaravone on the Levels of Serum IL-17,IL-6,and TNF-α in Patients with Acute Cerebral Infarction

Objective:To study effects of edaravone on the levels of serum interleukin-17(IL-17),IL-6,tumor necrosis factor-α(TNF-α) in patients with acute cerebral infarction.Methods: 63 patients of cerebral infarction were randomly divided and assigned to edaravone group and control group.31 patients in control group were treated by routine therapy of acute cerebral infarction two weeks.Another 32 patients in edaravone group were treated with routine therapy and edaravone for two weeks.The levels of serum IL-17,IL-6,and TNF-α were measured by enzyme-linked immunosorbent assay before treatment and after treatment 7d and 14d.Results: Although there were no difference before treatment and after treatment 7d,the levels of serum IL-17,IL-6,and TNF-α were found to be sharply decreased in edaravone group compared with the control group after treatment 14d.The levels of serum IL-17,IL-6,and TNF-α in two groups were lower significantly after treatment 7d and 14d than before treatment.Conclusions: Edaravone can decrease the levels of serum IL-17,IL-6,and TNF-α,which probably reduce the injury of ischemic brain and improve therapeutic efficacy.